Harpoon Therapeutics Inc (NASDAQ:HARP) has been assigned an average recommendation of “Buy” from the six ratings firms that are currently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating and five have given a buy rating to the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $23.75.
Several research firms have recently commented on HARP. Robert W. Baird began coverage on shares of Rocket Pharmaceuticals in a report on Monday, April 22nd. They issued an “outperform” rating for the company. Zacks Investment Research lowered shares of GENEL ENERGY PL/ADR from a “hold” rating to a “sell” rating in a report on Thursday, July 4th. Finally, Citigroup set a $27.00 price target on shares of PhaseBio Pharmaceuticals and gave the company a “buy” rating in a report on Friday, May 24th.
Several hedge funds and other institutional investors have recently bought and sold shares of HARP. Fosun International Ltd purchased a new position in Harpoon Therapeutics during the first quarter valued at approximately $3,062,000. Sphera Funds Management LTD. bought a new stake in shares of Harpoon Therapeutics in the 1st quarter worth about $3,133,000. New Leaf Venture Partners L.L.C. bought a new stake in shares of Harpoon Therapeutics in the 1st quarter worth about $27,666,000. Finally, MPM Asset Management LLC bought a new stake in shares of Harpoon Therapeutics in the 1st quarter worth about $39,796,000. 55.50% of the stock is owned by institutional investors and hedge funds.
Harpoon Therapeutics (NASDAQ:HARP) last announced its quarterly earnings data on Thursday, May 9th. The company reported ($0.92) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.45) by ($0.47). The business had revenue of $1.06 million for the quarter, compared to the consensus estimate of $1.40 million. Sell-side analysts anticipate that Harpoon Therapeutics will post -2.78 EPS for the current year.
About Harpoon Therapeutics
Harpoon Therapeutics, Inc, a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company's lead TriTAC product candidate is HPN424 that is in Phase I clinical trial for the treatment of metastatic castration-resistant prostate cancer.
Featured Story: What is the quiet period?
Receive News & Ratings for Harpoon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harpoon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.